BML (4694) Fundamentals 2026 — P/E 17.6x, Revenue Analysis | SniperIQ
BML (4694) is a JP-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of ¥134.4B, trading at ¥3585.00 on the JPX. This SniperIQ fundamentals page covers BML's valuation (P/E 17.6x, P/B 1.0x), profitability (net margin 5.2%), revenue (¥150.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is BML's market cap?
BML (4694) has a market capitalization of approximately ¥134.4B, trading at ¥3585.00 on the JPX. Market cap moves with the live share price.
What is BML's P/E ratio?
BML's trailing twelve-month P/E ratio is 17.6x, with a price-to-book (P/B) of 1.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is BML?
BML runs a net profit margin of 5.2%, a gross margin of 32.4%, and an operating margin of 6.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does BML generate?
BML reported revenue of ¥150.3B for fiscal year 2025, with net income of ¥7.7B and earnings per share (EPS) of 203.52. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does BML pay a dividend?
BML offers a trailing dividend yield of about 3.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is BML financially healthy?
BML carries a debt-to-equity ratio of 0.04x and a current ratio of 2.49x, with a market beta of 0.24. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is BML a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For BML (4694) the key facts are: market cap ¥134.4B, P/E 17.6x, revenue ¥150.3B, 52-week range 3370-4385. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track BML's full fundamentals live
Get BML's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.